4 Result(s)
within
Ruth A. Keri
Cancer Research
-
Article
Comprehensive characterization of protein–protein interactions perturbed by disease mutations
Technological and computational advances in genomics and interactomics have made it possible to identify how disease mutations perturb protein–protein interaction (PPI) networks within human cells. Here, we sh...
-
Article
Open AccessKLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therape...
-
Article
Open AccessFollistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
Follistatin (FST) is an intrinsic inhibitor of activin, a member of the transforming growth factor-β superfamily of ligands. The prognostic value of FST and its family members, the follistatin-like (FSTL) prot...
-
Article
Open AccessIntrinsic bias in breast cancer gene expression data sets
While global breast cancer gene expression data sets have considerable commonality in terms of their data content, the populations that they represent and the data collection methods utilized can be quite disp...
